Prospects of successful treatment of Parkinson's disease using apomorphine.

  • Iryna Karaban D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine
  • Nina Karasevych D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine
  • Tetyana Hasiuk D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine
Keywords: Parkinson's disease; apomorphine; pharmacokinetics; mechanism of action; clinical trials; indications: and contraindications

Abstract

Optimising the treatment of idiopathic Parkinson's disease is a complex, multifaceted and continuous process that directly affects quality of life. The main position of this examination is the need for individualised therapy that provides optimal motor function with the least negative consequences. Apomorphine, a dopamine agonist used as rescue therapy for patients with motor fluctuations with a potentially positive effect on non-motor symptoms, is the only antiparkinsonian drug whose ability to control motor symptoms is equivalent to that of levodopa. Subcutaneous injection is the most effective and affordable way to correct dopaminergic insufficiency in Parkinson's disease. The data of multi-centre studies presented in the review confirm the high efficiency, adequate tolerability, and prospects of using apomorphine in the complex pathogenetic therapy of the disease. This review provides historical background and summarises the structure, mechanism of action, pharmacodynamics, indications, contraindications, and side effects of subcutaneous apomorphine injections in the advanced stages of Parkinson's disease.

Author Biographies

Iryna Karaban, D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine

DSc (Medicine), Prof., Head of the Department of Clinical Physiology and Pathology of Extrapyramid Nervous System

Nina Karasevych, D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine

PhD (Medicine), Leading Researcher of the Department of Clinical Physiology and Pathology of Extrapyramid Nervous System

Tetyana Hasiuk, D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine

Researcher of the Department of Clinical Physiology and Pathology of Extrapyramid Nervous System

References

Colosimo, C.; De Michele, M. Motor fluctuations in Parkinson’s disease: pathophysiology and treatment. Eur J Neurol 1999, 6, 1-21. https://doi.org/10.1046/j.1468-1331.1999.610001.x

Olanow, C. W.; Gracies, J. M.; Goetz, C. G.; Stoessl, A. J.; Freeman, Th. et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson’s disease: a double blind video-based analysis. Mov Disord 2009, 24,3, 336-43 4. https://doi.org/10.1002/mds.22208

Witjas, T.; Kaphan, E.; Azulay, J. P.; Blin, O.; Ceccaldi, M. et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002, 59, 3, 408-13. https://doi.org/10.1212/wnl.59.3.408

Obeso, J. A.; Rodriguez-Oroz, M.; Marin, C.; Alonso, F.; Zamarbide, I.et al. The origin of motor fluctuations in Parkinson’s disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004, 62, 1, 1, S17-30. https://doi.org/10.1212/wnl.62.1_suppl_1.s17

Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson’s disease. Parkinsonism Relat Disord 2009, 15, 4, S18-23. https://doi.org/10.1016/s1353-8020(09)70829-6

Brotchie, J. M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005, 20, 8, 919-31. https://doi.org/10.1002/mds.20612

Kurlan, R.; Rothfield, K. P.; Woodward, W. R.; Nutt, J. G.; Miller, C. et al. Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 1988, 38, 3, 419-21. https://doi.org/10.1212/wnl.38.3.419

Nyholm, D.; Askmark, H.; Gomes-Trolin, C.; Knutson, T.; Lennernas, H. et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003, 26, 3, 156-63. https://doi.org/10.1097/00002826-200305000-00010

Jenner, P. Dopamine agonists in Parkinson’s disease–focus on non-motor symptoms. Eur J Neurol 2008, 15, 2, 1. https://doi.org/10.1111/j.1468-1331.2008.02211.x

Stocchi, F.; Nordera, G.; Marsden, C. D. Strategies for treating patients with advanced Parkinson’s disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997, 20, 2, 95-115. https://doi.org/10.1097/00002826-199704000-00001

Stocchi, F.; Ruggieri, S.; Vacca, L.; Olanow, C. W. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 2002, 125, 9, 2058-2066. https://doi.org/10.1093/brain/awf214

Lees, A. J. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam. Clin. Pharmacol. 1993,7, 121e128. https://doi.org/10.1111/j.1472-8206.1993.tb00226.x

Ernst, A. M. Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacologia 1965, 7, 391-399. https://doi.org/10.1007/BF00402361

Colosimo, C.; Merello, M.; Albanese, A. Clinical usefulness of apomorphine in movement disorders. Clin. Neuropharmacol. 1994, 17, 243-259. https://doi.org/10.1097/00002826-199406000-0000

Corsini, G. U.; Del Zompo, M.; Gessa, G. L.; Mangoni, A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979, 1, 954e956. https://doi.org/10.1016/s0140-6736(79)91725-2

Stibe, C.; Lees, A.; Stern, G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet 1987, 1, 871. https://doi.org/10.1016/s0140-6736(87)91660-6

Stibe, C. M.; Lees, A. J.; Kempster, P. A.; Stern, G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1998, 1, 403-406. https://doi.org/10.1016/s0140-6736(88)91193-2

Hughes, A. J.; Bishop, S.; Stern, G. M.; Lees, A. J. The motor response to repeated apomorphine administration in Parkinson's disease. Clin Neuropharmacol 1991, 14, 209-213. https://doi.org/10.1097/00002826-199106000-00003

Hughes A. J.; Lees, A. J.; Stern, G. M. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991, 54, 358-360. https://doi.org/10.1136/jnnp.54.4.358

Poewe, W.; Wenning, G. K Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000, 15, 789-794.

Poewe, W.; Lees, A.; Chaudhuri, K.R.; Isaacson, S. New perspectives in non-oral drug delivery in Parkinson's disease. Eur. Neurol. Rev. 2014, 9, 31-36. https://doi.org/10.17925/ENR.2014.09.01.i

Martinez-Martin, P.; Reddy, P.; Antonini, A.; Henriksen, T.; Katzenschlager, R. et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Park Dis 2011, 1, 197-203. https://doi.org/10.3233/jpd-2011-11037

Frankel, J. P.; Lees, A. J.; Kempster, P. A.; Stern, G. M. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990, 53, 2, 96-101. https://doi.org/10.1136/jnnp.53.2.96

Hilker, R.; Antonini, A.; Odin, P. What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 2011, 118, 6, 907-914. https://doi.org/10.1007/s00702-010-0555-8

Hardie, R. J.; Lees, A. J.; Stern, G. M. On-off fluctuations in Parkinson’s disease: a clinical and neuropharmacological study. Brain 1984, 107, 2, 487-506. https://doi.org/10.1093/brain/107.2.487

Stibe, C. M.; Lees, A. J.; Kempster, P. A.; Stern, G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988, 1, 8582, 403-406. https://doi.org/10.1016/S0140-6736(88)91193-2

Hilker, R.; Antonini, A.; Odin, P. What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 2011, 118, 6, 907-914. https://doi.org/10.1007/s00702-010-0555-8

Wenzel, K.; Homann, C. N.; Fabbrini, G.; Colosimo,C. The role of subcutaneous infusion of apomorphine in Parkinson’s disease. Expert Rev Neurother 2014, 14, 7, 833-843. https://doi.org/10.1586/14737175.2014.928202

Cotzias, G. C.; Papavasiliou, P. S.; Fehling, C.; Kaufman, B.; Mena, I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970, 282, 1, 31-33. https://doi.org/10.1056/NEJM197001012820107

Lees, A. J. Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundam Clin Pharmacol 1993, 7, 3-4, 121-128. https://doi.org/10.1111/j.1472-8206.1993.tb00226.x

Schwab, R. S.; Amador, L. V.; Lettvin, J. Y. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 1951, 56, 251-3.

Henriksen, T. Clinical insights into use of apomorphine in Parkinson’s disease: tools for clinicians. Neurodegener Dis Manag 2014, 4, 3, 271-282. https://doi.org/10.2217/nmt.14.17

Kleedorfer, B.; Turjanski, N.; Ryan, R.; Lees, A. J.; Milroy, C.; Stern, G. M. Intranasal apomorphine in Parkinson’s disease. Neurology 1991, 41, 5, 761-762. https://doi.org/10.1212/WNL.41.5.761-a

Hughes, A. J.; Webster, R; Bovingdon, M.; Lees, A. J. Stern, G. M. Sublingual apomorphine in the treatment of Parkinson’s disease complicated by motor fluctuations. Clin Neuropharmacol 1991, 14, 6, 556-561. https://doi.org/10.1097/00002826-199112000-00008

Manson, A. J.; Hanagasi, H.; Turner, K.; Patsalos, P. N.; Carey, P. et al. Intravenous apomorphine therapy in Parkinson’s disease: clinical and pharmacokinetic observations. Brain 2001, 124, 2, 331-340. https://doi.org/10.1093/brain/124.2.331

Menon, R.; Stacy, M. Apomorphine in the treatment of Parkinson’s disease. Expert Opin Pharmacother 2007, 8, 12, 1941-1950. https://doi.org/10.1517/14656566.8.12.1941

Millan, M.J.; Maiofiss, L.; Cussac, D.; Audinot, V.; Boutin, J. A.; Newman-Tancredi, A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002, 303, 791-804. https://doi.org/10.1124/jpet.102.039867

Dankova, J.; Bedard, P.; Langelier, P.; Poirier, L. J. Dopaminergic agents and circling behaviour. Gen Pharmacol 1978, 9, 295-302. https://doi.org/10.1016/0306-3623(78)90064-2

Newman-Tancredi, A.; Cussac, D.; Audinot, V.; Nicolas, J. P.; De Ceuninck, F. et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)- adrenoceptor. J Pharmacol Exp Ther 2002, 303, 805-814. https://doi.org/10.1124/jpet.102.039875

Antonini, A.; Tolosa, E.; Mizuno, Y.; Yamamoto, M.; Poewe, W. H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009, 8, 929-937. https://doi.org/10.1016/s1474-4422(09)70225-x

Feyder, M.; Bonito-Oliva, A.; Fisone, G. L-DOPA-Induced Dyskinesia and Abnormal Signaling n striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 2011, 5, 71. https://doi.org/10.3389/fnbeh.2011.00071

Guigoni, C.; Bezard, E. Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia. Park Relat Disord 2009, 3, 15, S64-S67. https://doi.org/10.1016/s1353-8020(09)70783-7

Mailman, R.; Huang, X.; Nichols, D. E. Parkinson's disease and D1 dopamine receptors. Curr Opin Investig 2001, 2, 1582-1591.

Blanchet, P. J.; Fang, J.; Gillespie, M.; Sabounjian, L.; Locke, K. W. et al. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol 1998, 21, 339-343.

Yoshimura, N.; Mizuta,E.; Kuno, S.; Sasa, M.; Yoshida, O. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Neuropharmacology 1993, 32, 315-321. https://doi.org/10.1016/0028-3908(93)90151-r

Andersson, K. E.; Treatment of overactive bladder: other drug mechanisms. Urology 2000, 55, 51-57. https://doi.org/10.1016/s0090-4295(99)00495-1

Seeman, P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 2015, 69, 183-189. https://doi.org/10.1002/syn.21805

Horowski, R.; Jahnichen, S.; Pertz, H. H. Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 2004, 19, 1523-1524.

Antonini, A.; Poewe, W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007, 6, 826-829. https://doi.org/10.1016/s1474-4422(07)70218-1

Andersohn, F.; Garbe, E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord 2009, 24, 129-133. https://doi.org/10.1002/mds.22385

Geerligs, L.; Meppelink, A. M.; Brouwer, W. H.; van Laar, T. The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study. Clin Neuropharmacol 2009, 32, 266-268. https://doi.org/10.1097/wnf.0b013e3181a6a92b

Borgemeester, R. W.; Lees, A. J.; van Laar, T. Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence. Park Relat Disord 2016, 27, 35-40. https://doi.org/10.1016/j.parkreldis.2016.04.023

Sharma, J. C.; Macnamara, L.; Hasoon, M.; Vassallo, M. Diagnostic and therapeutic value of apomorphine in Parkinsonian patients. Int J Clin Pract 2004, 58, 1028-1032. https://doi.org/10.1111/j.1368-5031.2004.00357.x

Hughes, A. J.; Lees, A. J.; Stern, G. M. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991, 54, 4, 358-360. https://doi.org/10.1136/jnnp.54.4.358

O’Sullivan, J. D.; Lees, A. J. Use of apomorphine in Parkinson’s disease. Hosp Med 1999, 60, 11, 816-820. https://doi.org/10.12968/hosp.1999.60.11.1236

Frankel, J. P.; Lees, A. J.; Kempster, P. A.; Stern, G. M. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990, 53, 2, 96-101. https://doi.org/10.1136/jnnp.53.2.96

Hagell, P.; Odin, P. Apomorphine in Parkinson’s disease. 3rd ed. UNI-MED: Bremen, 2014; p.95

Ramirez-Zamora, A.; Molho, E. Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions. Expert Rev Neurother 2014, 14, 1, 93-103. https://doi.org/10.1586/14737175.2014.868306

Obering, C. D.; Chen, J. J. Swope DM. Update on apomorphine for the rapid treatment of hypomobility (“off”) episodes in Parkinson’s disease. Pharmacotherapy 2006, 26, 6, 840-852. https://doi.org/10.1592/phco.26.6.840

Lees, A. J. Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundam Clin Pharmacol 1993, 7, 3-4, 121-128. https://doi.org/10.1111/j.1472-8206.1993.tb00226.x

Henriksen, T. Clinical insights into use of apomorphine in Parkinson’s disease: tools for clinicians. Neurodegener Dis Manag 2014, 4, 3, 271-282. https://doi.org/10.2217/nmt.14.17

Martinez-Martin, P.; Reddy, P.; Antonini, A.; Henriksen, T.; Katzenschlager, R. et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis 2011, 1, 2, 197-203. https://doi.org/10.3233/jpd-2011-11037

Menon, R.; Stacy, M. Apomorphine in the treatment of Parkinson’s disease. Expert Opin Pharmacother 2007, 8, 12, 1941-1950. https://doi.org/10.1517/14656566.8.12.1941Pessoa RR et al. Apomorphine: a review 847

Pfeiffer, R. F.; Gutmann, L.; Hull, K. L. Jr.; Bottini, P. B.; Sherry, J. H. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord 2007, 13, 2, 93100.https://doi.org/10.1016/j.parkreldis.2006.06.012

Kempster, P. A.; Frankel, J. P.; Stern, G. M.; Lees, A. J. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990, 53, 11, 1004-1007. https://doi.org/10.1136/jnnp.53.11.1004

Colosimo, C.; Merello, M.; Hughes, A. J.; Sieradzan, K.; Lees, A. J. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson’s disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996, 60, 6, 634-637. https://doi.org/10.1136/jnnp.60.6.634

Stibe, C.M.; Lees, A.J.; Kempster, P.A.; Stern, G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1998, 1, 403-406. https://doi.org/10.1016/s0140-6736(88)91193-2

Poewe, W.; Kleedorfer, B.; Wagner, M.; Benke, T.; Gasser, T.; Oertel, W. Sideeffects of subcutaneous apomorphine in Parkinson's disease. Lancet 1989, 1, 1084, 1050. https://doi.org/10.1016/s0140-6736(89)92487-2

Odin, P. Intermittent subcutaneous apomorphine injection. Odin, P.; P. Hagell, P.; Shing M. Eds., Apomorphine in Parkinson's Disease, 3 ed., UNIMED Verlag AG: Bremen, 2005; pp. 35-36.

Isaacson, S.; Lew, M.; Ondo, W.; Hubble, J.; Clinch,T.; Pagan, F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease. Movmnt Disords Clncl Pract 2016. http://dx.doi.org/10.1002/ mdc3.12350.

Colosimo, C.; De Michele, M. Motor fluctuations in Parkinson’s disease: pathophysiology and treatment. Eur J Neurol 1999, 6, 1-21. https://doi.org/10.1046/j.1468-1331.1999.610001.x

Golbe, L. I. Young-onset Parkinson’s disease: a clinical review. Neurology 1991, 41, 2, 1, 168-173. https://doi.org/10.1212/wnl.41.2_part_1.168

Olanow, C. W.; Gracies, J. M.; Goetz, C. G. et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson’s disease: a double blind video-based analysis. Mov Disord 2009, 24, 3, 336-343. https://doi.org/10.1002/mds.22208

Cotzias, G. C.; Papavasiliou, P. S.; Fehling, C.; Kaufman, B.; Mena, I. Similarities between neurologic effects of L-dipa and of apomorphine. N Engl J Med 1970, 282, 1, 31-33. https://doi.org/10.1056/nejm197001012820107

Stibe, C. M.; Lees, A. J.; Kempster, P. A.; Stern, G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988, 1, 8582, 403-406. https://doi.org/10.1016/s0140-6736(88)91193-2

Poewe, W.; Kleedorfer, B.; Wagner, M. et al. Side-effects of subcutaneous apomorphine in Parkinson’s disease. Lancet, 1989, 1, 8646, 1084-1085.

Kempster, P. A.; Iansek, R.; Larmour, I. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations. Aust N Z J Med 1991, 21, 3, 314-318. https://doi.org/10.1111/j.1445-5994.1991.tb04696.x

Hughes, A. J.; Bishop, S.; Kleedorfer, B.; Turjanski, N.; Fernandez, W. et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 1993, 8, 2, 165-170. https://doi.org/10.1002/mds.870080208

Merello, M.; Leiguarda, R. [Treatment of motor fluctuations in Parkinson’s disease with subcutaneous injections of apomorphine]. Medicina (B Aires) 1995, 55, 1, 5-10.

Ostergaard L, Werdelin L, Odin P, Lindvall, O.; Dupont E. et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995, 58, 6, 681-687. https://doi.org/10.1136/jnnp.58.6.681

Esteban Munoz, J.; Marti, M. J.; Marin, C.; Tolosa, E. Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations. Clin Neuropharmacol 1997, 20, 3, 245-252. https://doi.org/10.1097/00002826-199706000-00009

Pietz, K.; Hagell, P.; Odin, P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998, 65, 5, 709-716. https://doi.org/10.1136/jnnp.65.5.709

Dewey, R. B. Jr; Hutton, J. T.; LeWitt, P. A.; Factor, S. A. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001, 58, 9, 1385-1392. https://doi.org/10.1001/archneur.58.9.1385

Fahn, S.; Elton, R. UPDRS program members. Unified Parkinson’s Disease Rating Scale. In: Recent developments in Parkinsons disease. Fahn, S.; Marsden, C. D.; Goldstein, M.; Calne, D. B. Eds., Macmillan Healthcare Information, Florham Park, NJ: USA, 1987; pp. 153-63

Pfeiffer, R. F.; Gutmann, L.; Hull, K. L. Jr. et al. Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. The role of subcutaneous infusion of apomorphine in PD. Review. Parkinsonism Relat Disord 2007, 13, 2, 93-100.

Stacy, M. Apomorphine: north American clinical experience. Neurology 2004, 62, 6, 4, S18-21. https://doi.org/10.1212/wnl.62.6_suppl_4.s18

Pahwa, R.; Koller, W. C.; Trosch, R. M.; et al. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007, 258, 1-2, 137-143. https://doi.org/10.1016/j.jns.2007.03.013

Trosch, R. M.; Silver, D; Bottini, P. B. Intermittent subcutaneous apomorphine therapy for ’off’ episodes in Parkinson’s disease: a 6-month open-label study. CNS Drugs 2008, 22, 6, 519-527. https://doi.org/10.2165/00023210-200822060-00005

Isaacson, S. H.; Chaudhuri, K. R. Morning akinesia and the potential role of gastroparesis – managing delayed onset of first daily dose of oral levodopa in patients with Parkinson’s disease. Eur Neurol Rev 2013, 8, 2, 82-84. https://doi.org/10.17925/ENR.2013.08.02.82

Katzenschlager, R.; Poewe, W.; Rascol, O.; Trenkwalder, C; Deuschl, G. et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018, 17, 9, 749-759. http://dx.doi.org/10.1016/S1474-4422(18)30239-4

Nyholm, D.; Lennernas, H. Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin Drug Metab Toxicol 2008, 4, 193–203. https://doi.org/10.1517/17425255.4.2.193

Pahwa, R.; Lyons, K. E. Handbook of Parkinson’s Disease, 5th ed. CRC Press: Boca Raton, FL, 2013; p.51

Rizos, A.; Martinez-Martin, P.; Odin, P.; Antonini, A.; Kessel, B. et al. Characterizing motor and nonmotor aspects of early-morning off periods in Parkinson’s disease: an international multicenter study. Parkinsonism Relat Disord 2014, 20, 1231–1235. https://doi.org/10.1016/j.parkreldis.2014.09.013

Hauser, R. A.; Isaacson, S.; Clinch, T. The Tigan/Apokyn Study: randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 2014, 20, 1171–1176. https://doi.org/10.1016/j.parkreldis.2014.08.010

Goetz, C. G.; Tilley, B. C.; Shaftman, S. R.; Stebbins, G. T.; Fahn, S. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008, 23, 2129–70. https://doi.org/10.1002/mds.22340

Schlachetzki, J. C. M.; Barth, J.; Marxreiter, F.; Gossler, Ju.; Kohl, Z. et al (2017) Wearable sensors objectively measure gait parameters in Parkinson’s disease. PLoS One 2017, 12, e0183989–e0183918. https://doi.org/10.1371/ journal.pone.0183989

Gancher, S. T.; Bennett, W.; English, J.; Studies of renal function in animals chronically treated with apomorphine. Res Commun Chem Pathol Pharmacol 1989, 66, 163-166.

LeWitt, P. A. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004, 62, S8-S11. https://doi.org/10.1212/wnl.62.6_suppl_4.s8

van Laar, T.; Jansen, E. N.; Essink, A. W.; Neef, C.; Oosterloo, S. et al. R.A. Roos, A doubleblind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin Neurol Neurosurg 1993, 95, 231-235. https://doi.org/10.1016/0303-8467(93)90128-4

Ostergaard, L.; Werdelin, L.; Odin, P.; Lindvall, O.; Dupont, E. et al., Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995, 58, 681-687. https://doi.org/10.1136/jnnp.58.6.681

Dewey Jr., R. B.; Hutton, J. T.; LeWitt, P. A.; Factor, S. A. A randomized, doubleblind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001, 58, 1385-1392. https://doi.org/10.1001/archneur.58.9.1385

Pfeiffer, R. F.; Gutmann, L.; Hull Jr., K.L.; Bottini, P. B.; Sherry, J. H. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Park Rel Disord 2007, 13, 93-100. https://doi.org/10.1016/j.parkreldis.2006.06.012

R. Pahwa, W.C. Koller, R.M. Trosch, J.H. Sherry, Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose, J Neurol Sci 2007, 258, 137-143. https://doi.org/10.1016/j.jns.2007.03.013

Poltawski, L.; Edwards, H.; Todd, A.; Watson, T.; Lees, A.; James, C. A. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov Disord 2009, 24, 115-118. https://doi.org/10.1002/mds.22316

Hughes, A. J.; Lees, A. J.; Stern, G. M. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991, 54, 4, 358-360. https://doi.org/10.1136/jnnp.54.4.358

Hagell, P.; Odin, P. Apomorphine in Parkinson’s disease, 3rd ed. UNI-MED: Bremen, 2014; p.95

Hughes, A. J.; Lees, A. J.; Stern, G. M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990,336, 8706, 32-34. https://doi.org/10.1016/0140-6736(90)91531-E

Hughes, A. J.; Lees, A. J.; Stern, G. M. Apomorphine in the diagnosis and treatment of parkinsonian tremor. Clin Neuropharmacol 1990, 13, 4, 312-317. https://doi.org/10.1097/00002826-199008000-00005

Frankel, J. P.; Lees, A. J.; Kempster, P. A.; Stern, G. M. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990, 53, 2, 96-101. https://doi.org/10.1136/jnnp.53.2.96

Djamshidian, A.; Poewe, W. Apomorphine and levodopa in Parkinson’s disease: two revolutionary drugs from the 1950’s. Parkinsonism Relat Disord 2016, 33, 1, S9-12. https://doi.org/10.1016/j.parkreldis.2016.12.004

Henriksen, T. Clinical insights into use of apomorphine in Parkinson’s disease: tools for clinicians. Neurodegener Dis Manag 2014, 4, 3, 271-282. https://doi.org/10.2217/nmt.14.17

Hughes, A. J.; Bishop, S.; Lees, A. J; Stern, G. M.; Webster, R.; Bovingdon, M. Rectal apomorphine in Parkinson’s disease. Lancet 1991, 337, 8733, 118. https://doi.org/10.1016/0140-6736(91)90780-S

Kleedorfer, B.; Turjanski, N.; Ryan, R.; Lees, A. J.; Milroy, C.; Stern, G. M. Intranasal apomorphine in Parkinson’s disease. Neurology 1991, 41, 5, 761-762. https://doi.org/10.1212/WNL.41.5.761-a

Hughes, A. J.; Webster, R.; Bovingdon, M.; Lees, A. J.; Stern, G. M. Sublingual apomorphine in the treatment of Parkinson’s disease complicated by motor fluctuations. Clin Neuropharmacol 1991, 14, 6, 556-561. https://doi.org/10.1097/00002826-199112000-00008

Manson, A. J.; Hanagasi, H.; Turner, K.; Patsalos, P. N.; Carey, P. et al. Intravenous apomorphine therapy in Parkinson’s disease: clinical and pharmacokinetic observations. Brain 2001, 124, 2, 331-340. https://doi.org/10.1093/brain/124.2.331

Obering, C. D.; Chen, J. J.; Swope, D. M. Update on apomorphine for the rapid treatment of hypomobility (“off”) episodes in Parkinson’s disease. Pharmacotherapy 2006, 26, 6, 840-52. https://doi.org/10.1592/phco.26.6.840

Hughes, A. J.; Bishop, S.; Kleedorfer, B.; Turjanski, N.; Fernandez, W. et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 1993, 8, 2, 165-170. https://doi.org/10.1002/mds.870080208

Colosimo, C.; Merello, M.; Hughes, A. J.; Sieradzan, K.; Lees, A. J. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson’s disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996, 60, 6, 634-637. https://doi.org/10.1136/jnnp.60.6.634

Gunzler, S. A. Apomorphine in the treatment of Parkinson disease and other movement disorders. Expert Opin Pharmacother 2009, 10, 6, 1027-1038. https://doi.org/10.1517/14656560902828344

Ondo, W. G.; Hunter, C.; Ferrara, J. M.; Mostile, G. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord 2012, 18, 5, 619-622. https://doi.org/10.1016/j.parkreldis.2012.01.001

Kapoor, R.; Turjanski, N.; Frankel, J.; Kleedorfer, B.; Lees, A. et al. Intranasal apomorphine: a new treatment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990, 53, 11, p.1015. https://doi.org/10.1136/jnnp.53.11.1015

Melamed, E.; Offen, D.; Shirvan, A.; Ziv, I. Levodopa – on exotoxin or a therapeutic drug? J Neurol 2000, 247, 2, 135-139. https://doi.org/10.1007/pl00022914

Katunina, E.; Titova, N. The Epidemiology of Nonmotor Symptoms in Parkinson’s Disease (Cohort and Other Studies). Int Rev Neurobiol 2017, 133, 91–110. https://doi.org/10.1016/bs.irn.2017.05.012

Borgemeester, R. W. K.; Lees, A. J.; van Laar, T. Parkinson’s disease, visual hallucinations and apomorphine: a review of the available evidence. Park Relat Disord 2016, 27, 35–40. https://doi.org/10.1016/j.parkreldis.2016.04.023

Rosa-Grilo, M.; Qamar, M. A.; Evans, A.; Chaudhuri, K. R. The efcacy of apomorphine—a non-motor perspective. Park Relat Disord 2016, 33, S28–35. https://doi.org/10.1016/j.parkreldis.2016.11.020

Moore, T. J.; Glenmullen, J.; Mattison, D. R. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014, 174, 12, p. 1930. https://doi.org/10.1001/jamainternmed.2014.5262

Barbosa, P.; Lees, A. J.; Magee, C.; Djamshidian, A.; Warner, T. T. A retrospective evaluation of the frequency of impulsive compulsive behaviors in parkinson’s disease patients treated with continuous waking day apomorphine pumps. Mov Disord Clin Pract 2016, 4, 3, 323–328. https://doi.org/10.1002/mdc3.12416

Samuel, M.; Rodriguez-Oroz, M.; Antonini, A.; Brotchie, J.; Ray Chaudhuri, K. et al. Impulse control disorders in parkinson’s disease: management, controversies, and potential approaches HHS public access. Mov Disord 2015, 30, 2, 150–159. https://doi.org/10.1002/mds.26099

Himeno, E.; Ohyagi, Y.; Ma, L.; Nakamura, N.; Miyoshi, K. et al. Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neurol 2011, 69, 2, 248–256. https://doi.org/10.1002/ana.22319

Yarnall, A. J.; Lashley, T.; Ling, H.; Lees, A. J.; Coleman, S. Y. et al. Apomorphine: a potential modifer of amyloid deposition in Parkinson’s disease? Mov Disord 2016, 31, 5, 668–675. https://doi.org/10.1002/mds.26422

Fahn, S.; Oakes, D.; Shoulson, I.; Kieburtz, K.; Rudolph, A. et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004, 351, 2498–2508. https://doi.org/10.1056/nejmoa033447

Martinez-Martin, P.; Reddy, P.; Katzenschlager, R.; Antonini, A.; Todorova, A. et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord 2015, 30, 510–516. https://doi.org/10.1002/mds.26067

Trenkwalder, C.; Ray Chaudhuri, K.; Ruiz, P. J. G.; LeWitt, P.; Katzenschlager, R. et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease -- Clinical practice recommendations. Parkinsonism Relat Disord 2015, 21, 9, 1023-1030. https://doi.org/10.1016/j.parkreldis.2015.06.012

Cotzias, G. C.; Papavasilliou, P. S.; Fehling, C.; Kaufman, B.; Mena, I. Similarities between neurologic effects of L- dopa and of Apomorphine. N Engl J Med 1970, 282, 1, 31-33. https://doi.org/10.1056/nejm197001012820107

Published
2021-12-22
How to Cite
Karaban, I., Karasevych, N., & Hasiuk, T. (2021). Prospects of successful treatment of Parkinson’s disease using apomorphine . Ageing and Longevity, 2(4), 1-26. Retrieved from http://aging-longevity.org.ua/journal-description/article/view/39
Section
Статьи